MedPath

Linvoseltamab

Generic Name
Linvoseltamab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
M3CPC50MZS
Background

Linvoseltamab is an investigational bispecific antibody. It promotes the interaction of B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Phase 2
Recruiting
Conditions
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Smoldering Multiple Myeloma (SMM)
Interventions
Drug: Linvoseltamab
First Posted Date
2023-11-20
Last Posted Date
2025-01-09
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
104
Registration Number
NCT06140524
Locations
🇺🇸

Johns Hopkins Hospital, Baltimore, Maryland, United States

🇪🇸

Hospital Clinico Universitario Virgen De La Arrixaca, El Palmar, Murcia, Spain

🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 5 locations

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

Phase 3
Recruiting
Conditions
Relapsed Refractory Multiple Myeloma (RRMM)
Interventions
Drug: Linvoseltamab
Drug: Elotuzumab
Drug: Pomalidomide
Drug: Dexamethasone
First Posted Date
2023-02-15
Last Posted Date
2025-01-09
Lead Sponsor
Regeneron Pharmaceuticals
Target Recruit Count
380
Registration Number
NCT05730036
Locations
🇨🇱

Centro de Oncologia de Precision, Las Condes, Santiago, Chile

🇨🇱

Clinica Alemana de santiago, Santiago, Chile

🇯🇵

Iwate Medical University Hospital, Morioka, Iwate, Japan

and more 142 locations
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy